Hugo W. Moser Research Institute at Kennedy Krieger

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Hugo W. Moser Research Institute at Kennedy Krieger sits in the top decile of US sponsors by registered trial count (#295 of 15,742 sponsors by registered trial count).

73 total trials 17 currently recruiting 40 completed early-phase tilt top decile by trial count

Hugo W. Moser Research Institute at Kennedy Krieger: 73 sponsored US clinical trials, 17 recruiting.

Hugo W. Moser Research Institute at Kennedy Krieger sponsors 73 registered US clinical trials on ClinicalTrials.gov, 17 of them currently recruiting, and 40 completed. 4 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Autism Spectrum Disorder, with 5 trials.

Top-decile sponsor footprint

Hugo W. Moser Research Institute at Kennedy Krieger ranks in the top decile of sponsors by registered trial count (#295 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 48/100

40 of 48 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

73 total, page 2 of 2

COMPLETED Phase 2

Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder

NCT01694667

COMPLETED NA

Long Term Split Belt Treadmill Training for Stroke Recovery

NCT01646216

COMPLETED NA

Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy

NCT01594853

COMPLETED

National Child Traumatic Stress Network (NCTSN) Quality Improvement Initiative Database

NCT01591694

COMPLETED NA

Evaluating Intervention Responsiveness in People With Multiple Sclerosis

NCT01632293

COMPLETED Phase 2

Placebo Controlled Trial of Dextromethorphan in Rett Syndrome

NCT01520363

COMPLETED NA

Social Cognitive Development in Young Children With Autism

NCT01425918

COMPLETED NA

School-Age Children With Autism With Limited Expressive Language Skills

NCT01529580

COMPLETED NA

Virtual Sailing Simulator in Individuals With Spinal Cord Injury

NCT01491789

COMPLETED Phase 1

Functional Electrical Stimulation (FES) Driven Stepping in Individuals With Spinal Cord Injury

NCT01479777

COMPLETED NA

Exercise Training Program for Cerebellar Ataxia

NCT01307176

COMPLETED Phase 1

Locomotor Training for Neurological Disease

NCT01288040

TERMINATED Phase 2

Study on Functional Electrical Stimulation (FES) Cycling Following Spinal Cord Injury

NCT01217047

TERMINATED Phase 2

Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

NCT01168908

COMPLETED

Biomarker Development in Sturge-Weber Syndrome

NCT01345305

COMPLETED NA

A Randomized Clinical Trial for Toddlers With ASD

NCT01008800

TERMINATED Phase 1

Patterned Functional Electrical Stimulation (FES) Ergometry of Arm and Shoulder in Individuals With Spinal Cord Injury

NCT01005615

TERMINATED NA

Yulex Glove Prospective Study in Spina Bifida

NCT01133288

COMPLETED Early Phase 1

Yoga Based Psychotherapy Group Feasibility and Efficacy Study

NCT01524172

COMPLETED NA

Intervention for Toddlers at Risk for Autism Spectrum Disorders (ASD)

NCT01179841

TERMINATED Phase 2

Trial of Dextromethorphan in Rett Syndrome

NCT00593957

COMPLETED NA

School- and Home-Based Early Intervention for Toddlers With Autism

NCT00106210

TERMINATED Phase 2

Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy

NCT00004418

← Previous Page 2 of 2

What is open in the Hugo W. Moser Research Institute at Kennedy Krieger pipeline

17 recruiting of 73 indexed (23% open); 40 completed (55%).

Phase mix: 4 late (III/IV) vs 13 early (I/II) (early-phase heavy).

Top condition: Autism Spectrum Disorder (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Hugo W. Moser Research Institute at Kennedy Krieger: open-pipeline peers nationwide

Peers matched on 73 registered trials and 23% open enrollment, not the therapeutic-area sidebar.

Hugo W. Moser Research Institute at Kennedy Krieger sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080100 0%10%20%30%40% Total trials Recruiting share Hugo W. Moser Research Institute at Kennedy KriegerDenver Health and Hospital AuthorityJoslin Diabetes CenterMassachusetts Eye and Ear InfirmaryTulane UniversityMajor Extremity Trauma Research ConsortiumScripps HealthTexas A&M UniversityClemson University
Hugo W. Moser Research Institute at Kennedy Krieger sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Hugo W. Moser Research Institute at Kennedy Krieger sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 73 trials (± recruiting share)

Sponsors near 23% open enrollment (± trial volume)

What to do with this Hugo W. Moser Research Institute at Kennedy Krieger page

73 registered trials is a research-attention snapshot, not an endorsement of Hugo W. Moser Research Institute at Kennedy Krieger or any single study.

  • 17 of Hugo W. Moser Research Institute at Kennedy Krieger's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Autism Spectrum Disorder is the condition Hugo W. Moser Research Institute at Kennedy Krieger studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Autism Spectrum Disorder trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Hugo W. Moser Research Institute at Kennedy Krieger pipeline card: 73 registered trials from official public datasets.Report a data error.